Capricor's experimental cell therapy for Duchenne dystrophy rejected by US regulator
The US FDA turned down Capricor Therapeutics' experimental cell therapy for Duchenne muscular dystrophy, another setback for the biotech, Reuters reports.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The US Food and Drug Administration has refused to approve Capricor Therapeutics' investigational cell therapy. The treatment was aimed at Duchenne muscular dystrophy, a fatal inherited condition that gradually weakens muscles. The agency said so on Friday, according to Reuters, which first reported the decision.
The rejection adds to a series of regulatory setbacks the biotech company has already faced.
why it matters
For small biotech stocks, FDA decisions often act as the main catalyst for price moves, so a rejection typically weighs on the company's own shares. For the broader market the story stays local, but it is a reminder that regulatory risk in rare diseases remains significant.
market impact
Capricor shares: the FDA rejection lowers chances of a near-term market launch, pressuring the stock
- Capricor Therapeutics shares pressure down — the FDA rejection lowers chances of a near-term market launch
tags
instruments
sources
- US FDA declines to approve Capricor's cell therapy for Duchenne muscular dystrophy — Reuters, 20 November 2026 at 23:36 UTC
- US FDA declines to approve Capricor's cell therapy for Duchenne muscular dystrophy; shares slump — Reuters, 20 November 2026 at 23:44 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗